For instance, in the phase II, open-label, multi-cohort, multicentre ZENITH20 trial (NSCT03318939), a cohort of 115 NSCLC patients that have progressed after previous treatment with a proven EGFR or HER2 Ex20ins mutation who were treated with 16 mg poziotinib once daily achieved an ORR of 14.8% and a disease control rate (DCR) of 68.7% with a median PFS of 4.2 months [80]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.